Plasma samples from patients in the OPERA trial were examined for CXCL@ at treatment initiation and after @ months of treatment with either methotrexate plus placebo ( DMARD ) ( n = @ ) or methotrexate plus adalimumab ( DMARD + ADA ) ( n = @ ) .